The trail enrolled 123 patients at 23 sites across the US and Europe.
Jupiter Endovascular, Inc. announced completion of patient enrollment in the SPIRARE II pivotal clinical trial evaluating the c ...
Jupiter Endovascular announced that it completed patient enrollment in the SPIRARE II pivotal clinical trial evaluating its Vertex system.
MENLO PARK, Calif.--(BUSINESS WIRE)--Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using Endoportal Control TM to bring the precision and ...
Jupiter Endovascular completes enrollment in a pivotal trial of its Vertex system with Transforming Fixation technology for pulmonary embolectomy.
MENLO PARK, Calif.-- (BUSINESS WIRE)-- Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using Endoportal Controlâ„¢, announced today that the ...
Round Led by Sonder Capital with Participation from Senvest Management, LB Investment, and a New Strategic Corporate Investor MENLO PARK, Calif.--(BUSINESS WIRE)-- Jupiter Endovascular, Inc., a ...
Jupiter Endovascular, Inc., a medical technology company developing a new class of endovascular interventions using its proprietary Transforming Fixation (TFX) technology, today announced positive ...
Medical technology startup Jupiter Endovascular has closed on a round of Series B funding, surpassing its $40 million goal. The funding was led by investor group Sonder Capital, which has also ...
Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using its proprietary Transforming Fixation (TFX) technology, today announced it has closed ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results